Skip to main content
TipRanks
Go Ultimate75% OFF
Superluminal Medicines logo

Superluminal Medicines: Valuation, Funding & Investors

A biotechnology company integrating AI/ML, protein dynamics, and structural biology to discover therapies targeting challenging G protein-coupled receptors. The company develops next-generation small-molecule treatments for endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity.

Leadership & Board

Latest Estimated Valuation

Total Amount Raised
$60M
Total Funding Rounds
1
Latest Funding Amount
$60M
Latest Funding Round
Series B

Funding Round

Funding DateFunding RoundAmount RaisedPost-Money Valuation
Sep 03, 2026Series B$60.00M―

Investors

Investor NameFunding Round
Deep Track CapitalSeries B
Perceptive AdvisorsSeries B
RA Capital ManagementSeries B
Insight PartnersSeries B
NVIDIASeries B
Catalio Capital ManagementSeries B
Eli Lilly and CompanySeries B
CooleySeries B

Similar Companies

A snapshot of private companies similar to Superluminal Medicines, helping you discover and navigate related company profiles.

Related News and Analysis